DigiPath and Personalized Diagnostic Expand Digital Pathology into Chinese MarketDigiPath and Personalized Diagnostic Expand Digital Pathology into Chinese Market

Share Article

DigiPath, Inc. and Personalized Diagnostic, LLC, today announce they have entered in an agreement to expand DigiPath’s affordable, innovative, and reliable digital pathology solutions into the Chinese Market.

DigiPath, Inc. (OTCBB: DIGP) and Personalized Diagnostic, LLC, today announce they have entered in an agreement to expand DigiPath’s affordable, innovative, and reliable digital pathology solutions into the Chinese Market.

Personalized Diagnostics, L.L.C. will focus on brokering strategic partnerships between DigiPath and Chinese biotech companies. With the expansion of digital pathology, patients will have access to better expertise and care in this region.

“Personalized medicine and innovative health technologies have revolutionized medical practice in the United States, states Dr. Lana Feng, Founder and CEO of Personalized Diagnostics, LLC. “In China, personalized medicine is still in its infancy and companies look to the United States for new therapeutics and health technologies. In addition, healthcare reform is a top priority for the Chinese government and one of its key components is introducing more affordable healthcare solutions to the country. It is the right time for digital pathology to dramatically expand in China.”

“Combining DigiPath’s product's leading innovation and affordability, hundreds if not thousands of new digital pathology users will develop in China over the next five years,” said Eric Stoppenhagen, President and CFO of DigiPath. “Working with Dr. Lana Feng will position DigiPath with the most sought after partners in the Chinese market.”

To learn more about DigiPath’s digital pathology solutions, please see http://www.digipath.biz/solutions.html.

To learn more about partnering with DigiPath in the Chinese market, please email info(at)digipath(dot)biz.

About Personalized Diagnostic, LLC

Personalized Diagnostics, LLC is a biotech consulting firm focused on building partnerships between U.S. and Chinese companies in the personalized medicine and health technology space, which lead to better patient care. Dr. Lana Feng has spent 16 years in biotech industry with experiences ranging from product development to commercialization and business development. Her expertise is in cancer therapeutics and diagnostics, companion diagnostics and personalized medicine. Dr. Lana Feng obtained her Ph.D. from Indiana University in Bloomington and did her post-doctoral training at University of California, San Diego. She has a BS from Wuhan University in China.

About DigiPath, Inc.

DigiPath, Inc. provides the next generation of affordable, innovative, and reliable digital pathology solutions. DigiPath’s advisors bring over 60 years combined expertise in pioneering digital pathology, implementing over 750 installations at community pathology practices, hospitals, academic medical centers, reference laboratories, biopharma organizations, and life science research institutions worldwide. Please visit http://www.digipath.biz for more information.

SAFE HARBOR STATEMENT

This Press Release may contain certain forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. DigiPath has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect DigiPath's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause DigiPath's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. DigiPath undertakes no obligation to update or provide advice in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

DigiPath Media Relations
Visit website